Ed is a partner in our Corporate team and dual-qualified in England and Wales and California. He advises clients on strategic buy and sell-side M&A transactions, venture capital and growth equity financings, joint ventures, and restructurings, particularly within the technology and life sciences sectors.
Ed has extensive experience structuring, negotiating, and executing complex domestic and cross-border matters, regularly working across the UK, Europe, Nordics, and North America.
Ed is noted as a 'Key Lawyer' for mid-market M&A deals by Legal 500 UK 2025 and praised by clients for providing "the most exceptional service … always [going] above and beyond".
We have advised a syndicate of leading global life sciences investors including Access Biotechnology, Canaan Partners and SR One on their landmark US$140 million series A investment in Draig Therapeutics.
Press release
von Ed Chapman und Jack Coventry
Advising on Draig Therapeutics' US$140 million series A financing
von mehreren Autoren
Advising Grant Thornton UAE on its business combination with Grant Thornton Advisors LLC
von mehreren Autoren
von mehreren Autoren
von Kathleen Munstermann-Senff, LL.M. (Medizinrecht) und Dr. Martin Jäger
von mehreren Autoren
von Ulf Gosejacob und Victoria Theresa Meyer, LL.M. (Cape Town)
von mehreren Autoren
von mehreren Autoren
von Mareike Christine Gehrmann und Carla Nelles, LL.M. (Amsterdam)
von Dr. Robert Bauer
von mehreren Autoren